XPH Looks Tempting, but the Five-Year Chart Warns Investors
SPDR S&P Pharmaceuticals ETF has delivered a standout one-year run, yet the longer five-year view casts a shadow. The...
This page defines a benchmark index and explains how investors use it to assess relative performance and guide decision-making.
6,170 articlesSPDR S&P Pharmaceuticals ETF has delivered a standout one-year run, yet the longer five-year view casts a shadow. The...
KORU, the 3X South Korea ETF, tumbles about 28% in a single week even as it posted massive prior gains. The selloff u...
Hitting 60 is a pivotal moment. This guide explains how much you should have saved by 60, what to aim for in your 401...
New Fed minutes show policymakers worry that persistent energy costs could keep inflation above the 2% goal, even as ...
Two popular funds offer distinct approaches to U.S. financials. This guide breaks down cost, diversification, and str...
A new Fed chair can ripple through markets, but panic isn’t the right play. This article breaks down why chairman kev...
A yen-hedged approach to Japan equities outperformed the unhedged EWJ by roughly six percentage points in the first h...
Over five years, SPDR’s XLK delivered a 35-point edge on the S&P 500, even as a Feb 2026 pullback tested investor ner...
U.S. stocks declined as oil surged on Middle East tensions, with the S&P 500 and tech shares under pressure. Markets ...
Investors are weighing when the Fed will cut rates again and how those moves could reshape stock returns and portfoli...
Healthcare often proves more resilient than broader markets. This guide highlights three durable healthcare ETFs and ...
A dividend-focused ETF can bring balance to a growth-heavy portfolio. This guide breaks down schwab u.s. dividend equ...